{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T15:50:42Z","timestamp":1762876242980,"version":"build-2065373602"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,27]],"date-time":"2020-11-27T00:00:00Z","timestamp":1606435200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005616","name":"Allergan Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005616","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.jgar.2020.11.020","type":"journal-article","created":{"date-parts":[[2020,12,4]],"date-time":"2020-12-04T12:42:54Z","timestamp":1607085774000},"page":"48-52","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Antimicrobial activity of dalbavancin against clinical isolates of coagulase-negative staphylococci from the USA and Europe stratified by species"],"prefix":"10.1016","volume":"24","author":[{"given":"Helio S.","family":"Sader","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecilia G.","family":"Carvalhaes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer M.","family":"Streit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.J. Ryan","family":"Arends","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodrigo E.","family":"Mendes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2020.11.020_bib0005","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.cmi.2018.11.012","article-title":"Are coagulase-negative staphylococci virulent?","volume":"25","author":"Heilmann","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jgar.2020.11.020_bib0010","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s15010-016-0945-4","article-title":"Clinical significance of coagulase-negative staphylococci other than S. Epidermidis blood stream isolates at a tertiary care hospital","volume":"45","author":"Hitzenbichler","year":"2017","journal-title":"Infection"},{"key":"10.1016\/j.jgar.2020.11.020_bib0015","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.3390\/ijms20051215","article-title":"Coagulase-negative staphylococci pathogenomics","volume":"20","author":"Argemi","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jgar.2020.11.020_bib0020","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.idc.2018.06.005","article-title":"Prosthetic joint infection update","volume":"32","author":"Beam","year":"2018","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.jgar.2020.11.020_bib0025","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1128\/JCM.00846-17","article-title":"Is Staphylococcus lugdunensis significant in clinical samples?","volume":"55","author":"Argemi","year":"2017","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jgar.2020.11.020_bib0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0061161","article-title":"Microbiological and molecular characterization of Staphylococcus hominis isolates from blood","volume":"8","author":"Mendoza-Olazaran","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jgar.2020.11.020_bib0035","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1128\/AAC.06246-11","article-title":"Microbiological aetiology, epidemiology, and clinical profile of prosthetic joint infections: are current antibiotic prophylaxis guidelines effective?","volume":"56","author":"Peel","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2020.11.020_bib0040","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s12879-020-4841-2","article-title":"Staphylococcal species less frequently isolated from human clinical specimens\u2014are they a threat for hospital patients?","volume":"20","author":"Szemraj","year":"2020","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jgar.2020.11.020_bib0045","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s100960000299","article-title":"Glycopeptide resistance in coagulase-negative staphylococci","volume":"19","author":"Biavasco","year":"2000","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2020.11.020_bib0050","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1128\/CMR.00109-13","article-title":"Coagulase-negative staphylococci","volume":"27","author":"Becker","year":"2014","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jgar.2020.11.020_bib0055","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1128\/JCM.02098-09","article-title":"Decreased susceptibility to teicoplanin and vancomycin in coagulase-negative staphylococci isolated from orthopedic-device-associated infections","volume":"48","author":"Cremniter","year":"2010","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jgar.2020.11.020_bib0060","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1086\/323676","article-title":"Glycopeptide resistance among coagulase-negative staphylococci that cause bacteremia: epidemiological and clinical findings from a case\u2013control study","volume":"33","author":"Tacconelli","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2020.11.020_bib0065","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s40265-016-0666-0","article-title":"Single-dose dalbavancin: a review in acute bacterial skin and skin structure infections","volume":"77","author":"Garnock-Jones","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.jgar.2020.11.020_bib0070","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1128\/JCM.06746-11","article-title":"Comparative study using phenotypic, genotypic, and proteomics methods for identification of coagulase-negative staphylococci","volume":"50","author":"Loonen","year":"2012","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jgar.2020.11.020_bib0075","series-title":"CLSI standard M07","article-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2018"},{"key":"10.1016\/j.jgar.2020.11.020_bib0080","series-title":"CLSI supplement M100","article-title":"Performance standards for antimcirobial susceptibility testing","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2020"},{"year":"2020","series-title":"Breakpoint tables for interpretation of MICs and zone diameters. Version 10.0, January 2020","author":"European Committee on Antimicrobial Susceptibility Testing (EUCAST)","key":"10.1016\/j.jgar.2020.11.020_bib0085"},{"key":"10.1016\/j.jgar.2020.11.020_bib0090","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.diagmicrobio.2016.01.010","article-title":"Antimicrobial activity of ceftaroline and comparator agents when tested against numerous species of coagulase-negative Staphylococcus causing infection in US hospitals","volume":"85","author":"Sader","year":"2016","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2020.11.020_bib0095","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13756-019-0523-5","article-title":"The species distribution, antimicrobial resistance and risk factors for poor outcome of coagulase-negative staphylococci bacteraemia in China","volume":"8","author":"Cui","year":"2019","journal-title":"Antimicrob Resist Infect Control"},{"key":"10.1016\/j.jgar.2020.11.020_bib0100","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jiac.2015.02.012","article-title":"Optimizing antibiotic therapy of bacteremia and endocarditis due to staphylococci and enterococci: new insights and evidence from the literature","volume":"21","author":"Falcone","year":"2015","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jgar.2020.11.020_bib0105","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.idc.2008.10.001","article-title":"Coagulase-negative staphylococcal infections","volume":"23","author":"Rogers","year":"2009","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.jgar.2020.11.020_bib0110","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1310480","article-title":"Once-weekly dalbavancin versus daily conventional therapy for skin infection","volume":"370","author":"Boucher","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgar.2020.11.020_bib0115","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1080\/14656566.2019.1675637","article-title":"Important new therapies for methicillin-resistant Staphylococcus aureus","volume":"20","author":"Bassetti","year":"2019","journal-title":"Expert Opin Pharmacother"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716520303064?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716520303064?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:56:05Z","timestamp":1761990965000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716520303064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":23,"alternative-id":["S2213716520303064"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2020.11.020","relation":{},"ISSN":["2213-7165"],"issn-type":[{"type":"print","value":"2213-7165"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antimicrobial activity of dalbavancin against clinical isolates of coagulase-negative staphylococci from the USA and Europe stratified by species","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2020.11.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}